Bionano Genomics (BNGO) 10-Q 9 May 23 2023 Q1 Quarterly report Financial data

Cover

Cover - shares	3 Months Ended
	Mar. 31, 2023	May 04, 2023
Document Information [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2023
Document Transition Report	false
Entity File Number	001-38613
Entity Registrant Name	Bionano Genomics, Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	26-1756290
Entity Address, Address Line One	9540 Towne Centre Drive, Suite 100
Entity Address, City or Town	San Diego
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	92121
City Area Code	858
Local Phone Number	888-7600
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding (in shares)		306,790,214
Amendment Flag	false
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q1
Entity Central Index Key	0001411690
Current Fiscal Year End Date	--12-31
Common Stock
Document Information [Line Items]
Title of 12(b) Security	Common Stock, $0.0001 par value per share
Trading Symbol	BNGO
Security Exchange Name	NASDAQ
Warrants to purchase Common Stock
Document Information [Line Items]
Title of 12(b) Security	Warrants to purchase Common Stock
Trading Symbol	BNGOW
Security Exchange Name	NASDAQ

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 4,104	$ 5,091
Investments	91,704	108,095
Accounts receivable, net	6,780	7,022
Inventory	33,113	29,761
Prepaid expenses and other current assets	6,856	7,329
Total current assets	142,557	157,298
Restricted cash	400	400
Property and equipment, net	19,050	18,029
Operating lease right-of-use assets	7,062	7,222
Finance lease right-of-use assets	3,657	3,707
Intangible assets, net	39,351	41,143
Goodwill	77,289	77,289
Other long-term assets	2,785	2,414
Total assets	292,151	307,502
Current liabilities:
Accounts payable	15,780	12,534
Accrued expenses	9,250	10,552
Contract liabilities	1,127	871
Operating lease liability	2,235	2,260
Finance lease liability	282	285
Contingent consideration	9,461	9,382
Total current liabilities	38,135	35,884
Operating lease liability, net of current portion	5,043	5,504
Finance lease liability, net of current portion	3,612	3,619
Contingent consideration, net of current portion	13,680	12,970
Long-term contract liabilities	194	127
Total liabilities	60,664	58,104
Commitments and contingencies (Note 7)
Stockholders’ equity:
Preferred stock, $0.0001 par value; 10,000,000 shares authorized and no shares issued or outstanding as of March 31, 2023 and December 31, 2022	0	0
Common stock, $0.0001 par value, 400,000,000 shares authorized at March 31, 2023 and December 31, 2022; 306,790,000 and 297,183,000 shares issued and outstanding at March 31, 2023 and December 31, 2022, respectively	31	30
Additional paid-in capital	617,960	599,207
Accumulated deficit	(385,839)	(348,715)
Accumulated other comprehensive loss	(665)	(1,124)
Total stockholders’ equity	231,487	249,398
Total liabilities and stockholders’ equity	$ 292,151	$ 307,502

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2023	Dec. 31, 2022
Statement of Financial Position [Abstract]
Preferred stock, shares authorized (in shares)	10,000,000	10,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	400,000,000	400,000,000
Common stock, shares issued (in shares)	306,790,000	297,183,000
Common stock, shares outstanding (in shares)	306,790,000	297,183,000

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Revenue:
Total revenue	$ 7,415	$ 5,696
Operating expenses:
Total cost of revenue	5,345	4,835
Operating expenses:
Research and development	13,937	10,527
Selling, general and administrative	25,976	20,277
Total operating expenses	39,913	30,804
Loss from operations	(37,843)	(29,943)
Other income (expense):
Interest income	704	110
Interest expense	(76)	(77)
Other income (expense)	117	(33)
Total other income (expense)	745	0
Loss before income taxes	(37,098)	(29,943)
Benefit (provision) for income taxes	(26)	(9)
Net loss	$ (37,124)	$ (29,952)
Net loss per share, basic (in dollars per share)	$ (0.12)	$ (0.11)
Net loss per share, diluted (in dollars per share)	$ (0.12)	$ (0.11)
Weighted-average common shares outstanding, basic (in shares)	302,045	284,613
Weighted-average common shares outstanding, diluted (in shares)	302,045	284,613
Product revenue
Revenue:
Total revenue	$ 5,447	$ 4,206
Operating expenses:
Total cost of revenue	3,858	3,576
Service and other revenue
Revenue:
Total revenue	1,968	1,490
Operating expenses:
Total cost of revenue	$ 1,487	$ 1,259

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Statement of Comprehensive Income [Abstract]
Net loss:	$ (37,124)	$ (29,952)
Other comprehensive income (loss):
Unrealized gain (loss) on investment securities	423	(1,098)
Foreign currency translation adjustments	36	0
Other comprehensive income (loss)	459	(1,098)
Total comprehensive loss	$ (36,665)	$ (31,050)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Stockholders’ Equity (Deficit) (Unaudited) - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Accumulated Other Comprehensive Loss
Beginning balance (in shares) at Dec. 31, 2021		289,602,000
Beginning balance at Dec. 31, 2021	$ 337,118	$ 29	$ 553,747	$ (216,119)	$ (539)
Equity
Stock option exercises (in shares)		21,000
Stock option exercises	15		15
Stock-based compensation expense	5,102		5,102
Issuance of common stock due to the vesting of restricted stock units, net of shares withheld to cover taxes (in shares)		65,000
Net loss	(29,952)			(29,952)
Other comprehensive income (loss)	(1,098)				(1,098)
Ending balance (in shares) at Mar. 31, 2022		289,688,000
Ending balance at Mar. 31, 2022	$ 311,185	$ 29	558,864	(246,071)	(1,637)
Beginning balance (in shares) at Dec. 31, 2022	297,183,000	297,183,000
Beginning balance at Dec. 31, 2022	$ 249,398	$ 30	599,207	(348,715)	(1,124)
Equity
Stock option exercises (in shares)	42,000	42,000
Stock option exercises	$ 23		23
Stock-based compensation expense	3,882		3,882
Issue common stock, net of issuance costs (in shares)		9,500,000
Issue common stock, net of issuance costs	14,849	$ 1	14,848
Issuance of common stock due to the vesting of restricted stock units, net of shares withheld to cover taxes (in shares)		65,000
Net loss	(37,124)			(37,124)
Other comprehensive income (loss)	$ 459				459
Ending balance (in shares) at Mar. 31, 2023	306,790,000	306,790,000
Ending balance at Mar. 31, 2023	$ 231,487	$ 31	$ 617,960	$ (385,839)	$ (665)

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Operating activities:
Net loss	$ (37,124)	$ (29,952)
Adjustments to reconcile net loss to net cash used by operating activities:
Depreciation and amortization expense	3,190	2,210
Amortization of financing lease right-of-use asset	51	29
Amortization (accretion) of interest on securities	(82)	299
Non-cash lease expense	113	299
Net realized loss (gain) on investments	7	0
Stock-based compensation	3,882	5,102
Change in fair value of contingent consideration	789	79
Cost of leased equipment sold to customer	88	0
Changes in operating assets and liabilities:
Accounts receivable	242	(640)
Inventory	(5,707)	(5,938)
Prepaid expenses and other current assets	471	(323)
Other assets	(372)	(48)
Accounts payable	3,017	(3,168)
Accrued expenses and contract liabilities	(978)	(443)
Net cash used in operating activities	(32,413)	(32,494)
Investing Activities:
BioDiscovery acquisition, return of purchase consideration from escrow	0	694
Purchases of property and equipment	(360)	(150)
Purchase of available for sale securities	0	(14,954)
Sale and maturity of available for sale securities	16,888	47,179
Construction in progress	0	(832)
Sale of property and equipment	0	27
Net cash provided by investing activities	16,528	31,964
Financing activities:
Principal payments on financing lease liability	(10)	(8)
Proceeds from sale of common stock	15,229	0
Offering expenses on sale of common stock	(380)	0
Proceeds from warrant and option exercises	23	15
Net cash provided by financing activities	14,862	7
Effect of exchange rates on cash, cash equivalents and restricted cash	36	0
Net decrease in cash, cash equivalents and restricted cash	(987)	(523)
Cash, cash equivalents and restricted cash at beginning of period	5,491	24,571
Cash, cash equivalents and restricted cash at end of period	4,504	24,048
Reconciliation of cash, cash equivalents and restricted cash reported within the unaudited condensed consolidated balance sheets to the total amounts reported on the unaudited condensed consolidated statements of cash flows
Cash and cash equivalents	4,104	24,048
Restricted cash	400	0
Total cash, cash equivalents and restricted cash at end of period	4,504	24,048
Supplemental cash flow disclosures:
Cash paid for interest	76	70
Cash paid for operating lease liabilities	644	217
Supplemental disclosure of non-cash investing and financing activities:
Transfer of instruments and servers from property and equipment into inventory	0	544
Transfer of instruments and servers from inventory to property and equipment, net	2,356	2,056
Property and equipment included in accounts payable	230	0
Operating lease liabilities resulting from obtaining right-of-use assets	$ 0	$ 513

Organization and Basis of Prese

Organization and Basis of Presentation	3 Months Ended
	Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Basis of Presentation	Organization and Basis of Presentation Description of Business Bionano Genomics, Inc. (collectively, with its consolidated subsidiaries, the “Company”) is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Company offers optical genome mapping (“OGM”) solutions for applications across basic, translational and clinical research, and for other applications including bioprocessing. Through its Lineagen, Inc. (doing business as Bionano Laboratories, “Bionano Laboratories”) business, the Company also provides diagnostic testing for patients with clinical presentations consistent with autism spectrum disorder and other neurodevelopmental disabilities. Through its BioDiscovery, LLC (“BioDiscovery”) business, the Company also offers platform-agnostic software solution, which integrates next-generation sequencing and microarray data designed to provide analysis, visualization, interpretation and reporting of copy number variants, single-nucleotide variants and absence of heterozygosity across the genome in one consolidated view. Through our Purigen Biosystems Inc. (“Purigen”) business, we offer nucleic acid extraction and purification solutions using proprietary isotachophoresis (“ITP”) technology. Basis of Presentation The accompanying financial information has been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”) for interim reporting purposes. The condensed consolidated financial statements are unaudited. The unaudited condensed consolidated financial statements reflect, in the opinion of the Company’s management, all adjustments, consisting of only normal recurring adjustments, necessary for a fair presentation of financial position, results of operations, changes in equity, and comprehensive loss and cash flows for each period presented in accordance with United States generally accepted accounting principles (“U.S. GAAP”). All intercompany transactions and balances have been eliminated. The operating results presented in these unaudited interim condensed financial statements are not necessarily indicative of the results that may be expected for any future periods. These interim unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022. Reclassifications Certain amounts reported in prior years have been reclassified to conform with the presentation in the current year. These reclassifications had no effect on the reported results of operations. Liquidity and Going Concern The Company has experienced recurring net losses from operations, negative cash flows from operating activities, and accumulated deficit since its inception and expects to continue to incur net losses into the foreseeable future. As of March 31, 2023, the Company had approximately $4.1 million in cash and cash equivalents, $91.7 million in short term investments, and working capital of $104.4 million. The Company has an accumulated deficit of $385.8 million as of March 31, 2023. During the three months ended March 31, 2023, the Company used $32.4 million cash in operations. Management expects operating losses and negative cash flows to continue for at least the next year as the Company continues to incur costs related to research and commercialization efforts. Management has prepared cash flows forecasts which indicate that based on the Company’s expected operating losses and negative cash flows, there is substantial doubt about the Company’s ability to continue as a going concern within twelve months after the date that the unaudited condensed consolidated financial statements for the three months ended March 31, 2023, are issued. Management’s ability to continue as a going concern is dependent upon its ability to raise additional funding. Management’s plans to raise additional capital to fulfill its operating and capital requirements for at least 12 months include public or private equity or debt financings. However, the Company may not be able to secure such financing in a timely manner or on favorable terms, if at all. Furthermore, if the Company issues equity securities to raise additional funds, its existing stockholders may experience dilution, and the new equity securities may have rights, preferences and privileges senior to those of the Company’s existing stockholders. The unaudited condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and settlement of liabilities in the normal course of business, and do not include any adjustments to reflect the outcome of this uncertainty. Significant Accounting Policies During the three months ended March 31, 2023, there were no changes to the Company’s significant accounting policies as described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022. Recently Adopted Accounting Pronouncements In February 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-13, Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments (ASU 2016-13), which amends the impairment model by requiring entities to use a forward looking approach based on expected losses to estimate credit losses on certain types of financial instruments, including trade receivables and available for sale debt securities. For trade receivables and other instruments, entities will be required to use a new forward-looking expected loss model that generally will result in the earlier recognition of allowances for losses. For available-for-sale debt securities with unrealized losses, the losses will be recognized as allowances rather than as reductions in the amortized cost of the securities. The Company adopted ASU 2016-13 as of January 1, 2023.

Net Loss Per Share

Net Loss Per Share	3 Months Ended
	Mar. 31, 2023
Earnings Per Share [Abstract]
Net Loss Per Share	Net Loss Per Share Basic net loss per share is calculated by dividing the net loss by the weighted-average number of common shares outstanding for the period. Diluted net loss per share is computed by dividing the net loss by the weighted average number of common shares and common share equivalents outstanding for the period. Common share equivalents are only included when their effect is dilutive. The Company’s potentially dilutive securities which include outstanding warrants to purchase stock, restricted stock units (“RSUs”), performance stock units (“PSUs”), and outstanding stock options under the Company’s equity incentive plans have been excluded from the computation of diluted net loss per share as they would be anti-dilutive to the net loss per share. Restricted stock is treated as outstanding for accounting purposes. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding because all potentially dilutive securities were anti-dilutive. Potentially dilutive securities not included in the calculation of diluted net loss per share attributable to common stockholders because to do so would be anti-dilutive are as follows (in common stock equivalent shares): March 31, March 31, Stock options 32,013,000 21,531,000 Unvested restricted stock — 4,257,000 Warrants 4,356,000 4,356,000 RSUs 2,457,000 296,000 PSUs 290,000 290,000 Total 39,116,000 30,730,000

Revenue Recognition

Revenue Recognition	3 Months Ended
	Mar. 31, 2023
Revenue from Contract with Customer [Abstract]
Revenue Recognition	Revenue Recognition Revenue by Source Three Months Ended March 31, 2023 2022 Instruments $ 1,896,000 $ 1,596,000 Consumables 2,235,000 1,520,000 Software 1,316,000 1,090,000 Total product revenue 5,447,000 4,206,000 Service and other 1,968,000 1,490,000 Total revenue $ 7,415,000 $ 5,696,000 The Company has revised the classification of its revenue between the categories in the table above for the March 31, 2022 statement of operations. In the March 31, 2022 statement of operations, “software” was included in “service and other.” Revenue by Geographic Location Three Months Ended March 31, 2023 2022 $ % $ % Americas $ 3,444,000 47 % $ 3,328,000 58 % EMEA 2,992,000 40 % 1,739,000 31 % Asia Pacific 979,000 13 % 629,000 11 % Total $ 7,415,000 100 % $ 5,696,000 100 % The table above provides revenue from contracts with customers by source and geographic region (based on the customer’s billing address) on a disaggregated basis. Americas consists of North America and South America. EMEA consists of Europe, the Middle East, and Africa. Asia Pacific includes China, Japan, South Korea, Singapore, India and Australia. During the three months ended September 30, 2022, the Company changed the presentation of its revenues from India to be included in the Asia Pacific geographic region. Prior to the three months ended September 30, 2022, the Company had presented revenues from India in the EMEA geographic region. The impact of this change on prior period disclosures is immaterial. For the three months ended March 31, 2023 and 2022, the United States represented 41.2% and 45.0% of total revenue, respectively. No other countries represented greater than 10% of revenue during the three months ended March 31, 2023 and 2022. Remaining Performance Obligations As of March 31, 2023, the estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied was approximately $1.3 million. These remaining performance obligations primarily relate to extended warranty and support and maintenance obligations. The Company expects to recognize approximately 74.9% of this amount as revenue during the remainder of 2023, 20.5% in 2024, and 4.6% in 2025 and thereafter. Warranty revenue is included in service and other revenue. The Company recognized revenue of approximately $0.7 million and $0.3 million during the three months ended March 31, 2023 and 2022, respectively, which was included in the contract liability balance at the end of the previous year.

Balance Sheet Account Details

Balance Sheet Account Details	3 Months Ended
	Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Balance Sheet Account Details	Balance Sheet Account Details Accounts Receivable and Allowance for Credit Losses March 31, December 31, Accounts receivable, net: Accounts receivable, trade $ 7,030,000 $ 7,315,000 Allowance for credit losses (250,000) (293,000) $ 6,780,000 $ 7,022,000 Changes to the allowance for credit losses during the three months ended March 31, 2023 were as follows: Allowance for Credit Losses Balance as of January 1, 2023 $ (293,000) Provision for expected credit loss (5,000) Write-offs and payments 48,000 Balance as of March 31, 2023 $ (250,000) The Company's adoption of ASU No. 2016-13, Financial Instruments - Credit Losses, included an assessment of our aged trade receivables balances and their underlying credit risk characteristics. Our evaluation of past events, current conditions, and reasonable and supportable forecasts about the future resulted in an expectation of immaterial credit losses. Inventory The components of inventories are as follows: March 31, December 31, Inventory: Raw materials $ 5,800,000 $ 5,319,000 Work in process 10,003,000 7,055,000 Finished goods 17,310,000 17,387,000 $ 33,113,000 $ 29,761,000 Intangible Assets Intangible assets that are subject to amortization consisted of the following for the periods presented: March 31, 2023 December 31, 2022 Gross Carrying Amount Accumulated Amortization Net Carrying Amount Gross Carrying Amount Accumulated Amortization Net Carrying Amount Trade name $ 2,630,000 $ (684,000) $ 1,946,000 $ 2,630,000 $ (552,000) $ 2,078,000 Customer relationships 4,150,000 (1,379,000) 2,771,000 4,150,000 (1,172,000) 2,978,000 Developed technology 41,600,000 (7,068,000) 34,532,000 41,600,000 (5,615,000) 35,985,000 Intangibles, net $ 48,380,000 $ (9,131,000) $ 39,249,000 $ 48,380,000 $ (7,339,000) $ 41,041,000 Intangible assets not subject to amortization totaled $0.1 million at March 31, 2023 and December 31, 2022, and related to the Company’s domain name. Accrued Expenses Accrued expenses consist of the following: March 31, December 31, Compensation expenses $ 6,349,000 $ 7,002,000 Customer deposits 17,000 17,000 Taxes payable 848,000 825,000 Insurance 326,000 613,000 Professional fees and royalties 96,000 210,000 Warranty liabilities 591,000 489,000 Accrued clinical study fees 174,000 250,000 Other 849,000 1,146,000 Total $ 9,250,000 $ 10,552,000

Stockholders_ Equity and Stock-

Stockholders’ Equity and Stock-Based Compensation	3 Months Ended
	Mar. 31, 2023
Share-Based Payment Arrangement [Abstract]
Stockholders’ Equity and Stock-Based Compensation	Stockholders’ Equity and Stock-Based Compensation Cowen At-the-Market Facility On March 23, 2021, the Company entered into a Sales Agreement with Cowen and Company, LLC (“Cowen”) which provides for the sale, in the Company’s sole discretion, of shares of common stock having an aggregate offering price of up to $350.0 million through or to Cowen, acting as sales agent or principal, which was amended on March 9, 2023 to decrease the maximum aggregate offering price to $200.0 million for sales made on and after the date of the amendment (the “Cowen ATM”). The Company agreed to pay Cowen a commission of up to 3.0% of the aggregate gross proceeds from each sale of shares, reimburse legal fees and disbursements and provide Cowen with customary indemnification and contribution rights. In August 2022, the Company sold approximately 6.6 million shares of common stock under the Cowen ATM at an average share price of $3.46 per share, and received gross proceeds of approximately $23.1 million before deducting offering costs of $0.6 million. During the first quarter of 2023, the Company sold approximately 9.5 million shares of common stock under the Cowen ATM at an average share price of $1.60 per share, and received gross proceeds of approximately $15.2 million before deducting offering costs of $0.4 million. Stock Warrants A summary of the Company’s warrant activity during the three months ended March 31, 2023 was as follows: Shares of Stock under Warrants Weighted- Weighted- Aggregate Outstanding at January 1, 2023 4,356,000 $ 5.96 0.76 $ 273,000 Granted — — — — Exercised — — — — Canceled — — — — Outstanding at March 31, 2023 4,356,000 $ 5.96 0.52 $ 156,000 Stock Options A summary of the Company’s stock option activity during the three months ended March 31, 2023 was as follows: Shares of Stock under Stock Options Weighted- Weighted- Aggregate Outstanding at January 1, 2023 24,022,000 $ 3.28 8.50 $ 2,068,000 Granted 9,121,000 1.60 — Exercised (42,000) 0.55 — 25,000 Canceled (1,088,000) 3.37 — Outstanding at March 31, 2023 32,013,000 $ 2.80 8.84 $ 1,147,000 Vested and exercisable at March 31, 2023 9,149,000 $ 3.56 7.89 $ 892,000 For the three months ended March 31, 2023, the weighted-average grant date fair value of stock options granted was $1.07 per share. Stock-Based Compensation The Company recognized stock-based compensation expense for the periods presented as follows: Three Months Ended 2023 2022 Cost of product revenue $ 102,000 $ — Cost of service and other revenue 44,000 — Research and development 1,357,000 3,328,000 General and administrative 2,379,000 1,774,000 Total stock-based compensation expense $ 3,882,000 $ 5,102,000 The weighted-average assumptions used in the Black-Scholes option pricing model to determine the fair value of the employee stock option grants during the periods presented were as follows: Three Months Ended 2023 2022 Risk-free interest rate 4.0 % 1.9 % Expected volatility 72.7 % 70.1 % Expected term (in years) 6.0 6.0 Expected dividend yield 0.0 % 0.0 % Restricted Stock Restricted Stock A restricted stock award in the amount of 5.0 million shares with a grant date fair value of $5.20 a share was granted as part of the acquisition of BioDiscovery. One-third of the Restricted Shares was scheduled to vest on October 18, 2022 and one-twelfth of the Restricted Shares was scheduled to vest every three months following October 18, 2022, subject to continuous service of the key employee. The fair value of the restricted stock award was based on the market value of common stock as of the date of grant and was amortized to stock-based compensation expense over the service period. On October 4, 2022, the restricted stock award was modified due to the change in employment status of the key employee from full time to emeritus. As a result of the modification, the restricted stock award vested in full on October 4, 2022. The award was revalued on the modification date, resulting in a modified grant date fair value of $2.04 a share ($15.8 million less than the initial grant date fair value of the award). The fair value of the modified restricted stock award was based on the market value of common stock as of the modification date. Restricted Stock Units and Performance Stock Units The following table summarizes RSU activity during the three months ended March 31, 2023: Stock Units Weighted- Average Grant Date Fair Value per Share Outstanding at January 1, 2023 96,000 $ 4.74 Granted 2,461,000 1.63 Released (65,000) 4.74 Forfeited (35,000) 1.63 Outstanding at March 31, 2023 2,457,000 $ 1.67 The total intrinsic value of the RSUs that vested during the three months ended March 31, 2023 was $0.3 million, determined as of the date of vesting. The weighted average remaining contractual term for the RSUs is 3.5 years as of March 31, 2023. The following table summarizes PSU activity during the three months ended March 31, 2023: Stock Units Weighted- Average Grant Date Fair Value per Share Outstanding at January 1, 2023 290,000 $ 4.74 Granted — — Released — — Forfeited — — Outstanding at March 31, 2023 290,000 $ 4.74 The weighted average remaining contractual term for the PSUs is 2.1 years as of March 31, 2023. Executive Option Grants and RSUs On February 15, 2023, the compensation committee of the Company’s board of directors granted various executive officers stock options to purchase an aggregate of 3.3 million shares of common stock at an exercise price of $1.63 per share, and RSUs amounting to 0.7 million shares of common stock at a grant date fair value of $1.63 per share, in each case with an effective grant date and vesting commencement date of February 15, 2023 (the “Grant Date”). These stock option grants and RSUs were issued from the 2018 Plan. The shares subject to the option shall vest monthly over 48 months beginning on the one-month anniversary of the Grant Date, such that the option shall be fully vested and exercisable on the four-year anniversary of the Grant Date. The RSUs shall vest annually over four years beginning one year after the Grant Date, and the balance of the shares vest in a series of three successive equal annual installments measured from the first anniversary of the Grant Date, such that the RSU shall be fully vested on the four-year anniversary of the Grant Date. Series A Preferred Stock On April 13, 2023, the Company entered into an agreement with David Barker, the Chair of the Company’s board of directors, pursuant to which the Company agreed to issue and sell one share of the Company’s Series A Preferred Stock, par value $0.0001 per share for a purchase price of $100.00. The closing of the sale and purchase of the share of Series A Preferred was completed on April 13, 2023. The share of Series A Preferred will have 3.0 billion votes, but has the right to vote only on a proposal submitted to the stockholders of the Company to adopt an amendment, or a series of alternate amendments, to the Company’s Amended and Restated Certificate of Incorporation, as amended, to combine the outstanding shares of Common Stock into a smaller number of shares of Common Stock at a ratio specified in or determined in accordance with the terms of such amendment or series of alternate amendments (“Reverse Stock Split Proposal”), and will have no voting rights (i) except with respect to a Reverse Stock Split Proposal and the votes of the share of Series A Preferred are required to be cast for and against such Reverse Stock Split Proposal in the same proportion as shares of Common Stock are voted for and against such Reverse Stock Split Proposal (with any shares of Common Stock that are not voted, whether due to abstentions, broker non-votes or otherwise not counted as votes for or against a Reverse Stock Split Proposal) and (ii) unless the holders of one-third (1/3rd) of the outstanding shares of Common Stock are present and vote, in person or by proxy, at the meeting of stockholders at which a Reverse Stock Split Proposal is submitted for stockholder approval (or any adjournment thereof). The share of Series A Preferred will vote together with the Common Stock as a single class on a Reverse Stock Split Proposal. The Series A Preferred has no other voting rights, except as may be required by the General Corporation Law of the State of Delaware. The outstanding share of Series A Preferred will be redeemed in whole, but not in part, for a redemption price of $100.00, payable out of funds lawfully available therefor, (i) if such redemption is ordered by the Company’s Board of Directors in its sole discretion, automatically and effective on such time and date specified by the Board of Directors in its sole discretion, or (ii) automatically immediately following the approval by the stockholders of a Reverse Stock Split Proposal.

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies The Company has entered into various operating lease agreements and a finance lease agreement, primarily relating to our office, laboratory, and manufacturing space. See Note 11 – Commitments and Contingencies, subsection titled “Leases”, in Part II, Item 8 of the Annual Report on Form 10-K for the year ended December 31, 2022 for information regarding the Company’s lease agreements. The future minimum payments under non-cancellable operating and finance leases as of March 31, 2023, are as follows: Operating Leases Finance Lease Remainder of 2023 $ 1,942,000 $ 242,000 2024 2,684,000 330,000 2025 2,788,000 338,000 2026 729,000 347,000 2027 255,000 356,000 Thereafter — 5,594,000 Total future lease payments 8,398,000 7,207,000 Less: imputed interest (1,120,000) (3,313,000) Total lease liabilities $ 7,278,000 $ 3,894,000 Litigation From time to time, the Company may be subject to potential liabilities under various claims and legal actions that are pending or may be asserted. These matters arise in the ordinary course and conduct of the business. The Company regularly assesses contingencies to determine the degree of probability and range of possible loss for potential accrual in the unaudited condensed consolidated financial statements. An estimated loss contingency is accrued in the unaudited condensed consolidated financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Based on the Company’s assessment, it currently does not have any material loss exposure as it is not a defendant in any claims or legal actions. Contingent Consideration

Acquisitions

Acquisitions	3 Months Ended
	Mar. 31, 2023
Business Combination and Asset Acquisition [Abstract]
Acquisitions	Acquisitions Purigen Acquisition In November 2022, the Company completed the acquisition of Purigen Biosystems, Inc. for approximately $32.0 million in cash and up to an aggregate of $32.0 million in cash payable based on the achievement of certain milestones. Cash of $1.2 million will be held in an escrow fund for purposes of satisfying any post-closing purchase price adjustments and indemnification claims under the Purigen Merger Agreement. The purchase price allocation for the acquisition of Purigen is preliminary and subject to revision as additional information about the fair value of assets and liabilities becomes available. As permitted under ASC 805, the Company is allowed a measurement period, which may not exceed one year, in which to complete its accounting for the acquisition. Per the terms of the Purigen Merger Agreement, the purchase price is still subject to adjustment for the final determination of cash, unpaid indebtedness, unpaid transaction expenses and working capital, as well for deferred and current tax assets and liabilities. The following is the estimated purchase price for the acquisition of Purigen: Cash $ 32,034,000 Estimated fair value of milestone consideration 12,970,000 Estimated return of cash to buyer from escrow (90,000) Total estimated purchase price $ 44,914,000 The total estimated purchase price was allocated to Purigen’s tangible and identifiable intangible assets acquired and liabilities assumed based on their estimated fair values as of the acquisition date, with the excess recorded as goodwill, as follows: Cash & cash equivalents $ 290,000 Accounts receivable 259,000 Inventory 944,000 Prepaid expenses and other current assets 184,000 Property and equipment, net 805,000 Restricted cash 400,000 Operating lease right-of-use assets 1,636,000 Other long-term assets 533,000 Intangible assets 20,000,000 Goodwill 22,651,000 Accounts payable and other accrued liabilities (1,152,000) Operating lease liability (short-term and long-term) (1,636,000) Net assets acquired $ 44,914,000 The acquisition date fair values of identifiable intangible assets acquired are as following: Developed technology $ 18,800,000 Customer relationships 200,000 Tradename 1,000,000 Fair value of identifiable intangible assets $ 20,000,000 The Company uses the income approach to derive the fair value of the identified intangible assets acquired. This approach calculates fair value by estimating future cash flows attributable to the assets and then discounting these cash flows to a present value using a risk-adjusted discount rate. The customer relationships and trade name intangibles are being amortized on a straight-line basis over their estimated useful lives of 5 years. The developed technology intangible is being amortized on a straight-line basis over its estimated useful live of 15 years. Straight-line amortization was determined to be materially consistent with the pattern of expected use of the intangible assets. As the Company began integrating Purigen’s operations with its existing operations during the fourth quarter of 2022, it is not practical or meaningful to distinguish Purigen’s expenses or net income or loss from that of the combined operations. Pro forma Financial Information The unaudited pro forma financial information in the table below summarizes the combined results of operations for the Company and Purigen as if the companies had been combined as of the beginning of the year prior to the acquisition. These amounts have been calculated after applying the Company’s accounting policies and adjusting the results of Purigen to reflect the additional amortization that would have been charged assuming the fair value adjustments to intangible assets had been applied at the beginning of the year prior to the acquisition. The following unaudited pro forma financial information is for informational purposes only and is not necessarily indicative of the results of operations that would have been achieved as if the acquisition had taken place as of January 1, 2021. Three Months Ended March 31, 2022 Revenue $ 6,220,000 Net loss (32,048,000) Basic and diluted net loss per share $ (0.11)

Investments and Fair Value Meas

Investments and Fair Value Measurements	3 Months Ended
	Mar. 31, 2023
Fair Value Disclosures [Abstract]
Investments and Fair Value Measurements	Investments and Fair Value Measurements The Company holds investment securities that consist of highly liquid, investment grade debt securities. The Company determines the fair value of its investment securities based upon one or more valuations reported by its investment accounting and reporting service provider. The investment service provider values the securities using a hierarchical security pricing model that relies primarily on valuations provided by an industry-recognized valuation service. Such valuations may be based on trade prices in active markets for identical assets or liabilities (Level 1 inputs) or valuation models using inputs that are observable either directly or indirectly (Level 2 inputs), such as quoted prices for similar assets or liabilities, yield curves, volatility factors, credit spreads, default rates, loss severity, current market and contractual prices for the underlying instruments or debt, and broker and dealer quotes, as well as other relevant economic measures. The following table presents the Company’s financial assets and liabilities measured at fair value on a recurring basis as of March 31, 2023 and December 31, 2022: March 31, 2023 Total Fair Value and Carrying Value on Balance Sheet Fair Value Measurement Category Level 1 Level 2 Level 3 Assets: Commercial paper $ 15,216,000 $ — $ 15,216,000 $ — Corporate notes/bonds 74,500,000 — 74,500,000 — Securities of government sponsored entities 1,988,000 — 1,988,000 — Total investments: $ 91,704,000 $ — $ 91,704,000 $ — Money market funds $ 252,000 $ 252,000 $ — $ — Liabilities: Contingent consideration $ 23,141,000 $ — $ — $ 23,141,000 December 31, 2022 Total Fair Value and Carrying Value on Balance Sheet Fair Value Measurement Category Level 1 Level 2 Level 3 Assets: Commercial paper $ 20,020,000 $ — $ 20,020,000 $ — Corporate notes/bonds 86,094,000 — 86,094,000 — Securities of government sponsored entities 1,981,000 1,981,000 Total investments: $ 108,095,000 $ — $ 108,095,000 $ — Money market funds $ 1,868,000 $ 1,868,000 $ — $ — Liabilities: Contingent consideration $ 22,352,000 $ — $ — $ 22,352,000 Money Market Funds are classified as cash equivalents on the unaudited condensed consolidated balance sheet. Contingent Consideration Contingent consideration relates to the acquisitions of BioDiscovery and Purigen. The outcome of the milestone consideration for all contingent consideration liabilities is binary, meaning the milestones are either achieved or not achieved, and the only other variable factor is the timing of when the milestones are achieved. The fair value measurement of the contingent consideration liabilities is based on significant inputs not observed in the market (Level 3 inputs). These unobservable inputs represent a Level 3 measurement because they are supported by little or no market activity and reflect the Company’s assumptions in measuring fair value. The fair value of the BioDiscovery contingent consideration liability is reassessed on a quarterly basis using a probability weighted model. Assumptions used to estimate the acquisition date fair value of the contingent consideration related to the acquisition of BioDiscovery include the probability of achieving, or changes in timing, of certain milestones, and a discount rate. As of March 31, 2023 a discount rate of 3% was used. The Company determined the fair value of the BioDiscovery milestone consideration using a scenario-based technique, as the trigger for payment is event driven. The Company determined it is highly likely that the milestone related to the BioDiscovery acquisition will be achieved and therefore used a 95% probability factor which is applied to the $10.0 million milestone consideration. The change in fair value of the contingent consideration during the three months ended March 31, 2023 was due to the passage of time. Contingent consideration liabilities related to the Purigen milestones are related to the achievement of two independent milestones with aggregate possible milestone payments totaling $32.0 million. The fair value of the Purigen milestones are reassessed on a quarterly basis using a probability weighted model and a Monte Carlo Simulation. Assumptions used to estimate the acquisition date fair value of the milestones using a probability weighted model include the probability of achieving, or changes in timing, of independent milestones, and a discount rate of 15%. The Company determined the fair value of this milestone consideration using a scenario-based technique, as the trigger for payment is event driven. The Company determined the likelihood of each independent milestone and used probability factors ranging from 20% to 80% which were applied to the individual payments. A Monte Carlo Simulation was performed to determine the likelihood that the milestone will be achieved and was applied to the milestone consideration payment. Changes in estimated fair value of contingent consideration liability in the three months ended March 31, 2023 is as follows: Contingent Consideration Liability (Level 3 Measurement) Balance as of January 1, 2023 $ 22,352,000 Liability recorded as a result of current period acquisition — Change in estimated fair value, recorded in selling, general and administrative expenses 789,000 Cash payments — Balance as of March 31, 2023 $ 23,141,000 Available for Sale Investments The Company invests its excess cash in U.S. Treasury and agency securities, corporate debt securities, and commercial paper, which are classified as available-for-sale investments. These investments are carried at fair value and are included in the tables below. The Company records an allowance for credit losses when unrealized losses are due to credit-related factors. At each reporting date, the Company evaluates securities with unrealized losses to determine whether such losses, if any, are due to credit-related factors. The Company evaluates, among others, whether the Company has the intention to sell any of these investments and whether it is not more likely than not that the Company will be required to sell any of them before recovery of the amortized cost basis. Neither of these criteria were met in any period presented. The credit ratings of the securities held remain of the highest quality. Moreover, the Company continues to receive payments of interest and principal as they become due, and our expectation is that those payments will continue to be received timely. Based on this evaluation, as of March 31, 2023 and December 31, 2022, the Company determined that unrealized losses of the below securities were primarily attributable to changes in interest rates and non-credit related factors. As such, no allowances for credit losses were recorded during these periods. As of March 31, 2023 and December 31, 2022, the Company held 17 and 16 securities, respectively, which have been in an unrealized loss position for a period of less than 12 months. As of March 31, 2023 and December 31, 2022, the Company held 19 and 24 securities, respectively, which have been in an unrealized loss position for a period of greater than 12 months. Realized gains and losses are calculated using the specific identification method and recorded in other income (expense) in the Company’s unaudited condensed consolidated statements of operations and comprehensive loss. The Company has the ability, if necessary, to liquidate any of its cash equivalents and marketable securities to meet its liquidity needs in the next 12 months. Interest receivable as of March 31, 2023 and December 31, 2022 was $0.6 million and $0.5 million, respectively, and is recorded as a component of prepaid expenses and other current assets on the unaudited condensed consolidated balance sheets. As of March 31, 2023, the following table summarizes the amortized cost and the unrealized gains/losses of the available for sale securities: Remaining Contractual Maturity (in years) Amortized Cost Unrealized Gains Unrealized Losses Aggregate Estimated Fair Value Commercial paper Less than 1 $ 15,259,000 $ — $ (43,000) $ 15,216,000 Corporate notes/bonds Less than 1 68,739,000 — (561,000) 68,178,000 Securities of government sponsored entities Less than 1 1,998,000 — (10,000) 1,988,000 Total maturity less than 1 year $ 85,996,000 $ — $ (614,000) $ 85,382,000 Corporate notes/bonds 1 to 5 6,372,000 — (50,000) 6,322,000 Total $ 92,368,000 $ — $ (664,000) $ 91,704,000 As of December 31, 2022, the following table summarizes the amortized cost and the unrealized gains/losses of the available for sale securities: Remaining Contractual Maturity (in years) Amortized Cost Unrealized Gains Unrealized Losses Aggregate Estimated Fair Value Commercial paper Less than 1 $ 20,093,000 $ — $ (73,000) $ 20,020,000 Corporate notes/bonds Less than 1 72,823,000 1,000 (911,000) 71,913,000 Securities of government sponsored entities Less than 1 1,998,000 — (16,000) 1,982,000 Total maturity less than 1 year $ 94,914,000 $ 1,000 $ (1,000,000) $ 93,915,000 Corporate notes/bonds 1 to 5 14,268,000 — (88,000) 14,180,000 Total $ 109,182,000 $ 1,000 $ (1,088,000) $ 108,095,000 As of March 31, 2023, the following table summarizes available-for-sale securities in an unrealized loss position with no credit losses reported: Less Than 12 Months 12 Months or Greater Total Fair Value Gross Unrealized Loss Fair Value Gross Unrealized Loss Fair Value Gross Unrealized Loss Commercial paper $ 15,216,000 $ (43,000) $ — $ — $ 15,216,000 $ (43,000) Corporate Notes/Bonds 11,687,000 (40,000) 62,813,000 (571,000) 74,500,000 (611,000) Securities of Government Sponsored Entities 1,988,000 (10,000) — — 1,988,000 (10,000) Total $ 28,891,000 $ (93,000) $ 62,813,000 $ (571,000) $ 91,704,000 $ (664,000) As of December 31, 2022, the following table summarizes available-for-sale securities in an unrealized loss position with no credit losses reported: Less Than 12 Months 12 Months or Greater Total Fair Value Gross Unrealized Loss Fair Value Gross Unrealized Loss Fair Value Gross Unrealized Loss Commercial paper $ 20,020,000 $ (73,000) $ — $ — $ 20,020,000 $ (73,000) Corporate Notes/Bonds 9,661,000 (27,000) 74,452,000 (972,000) 84,113,000 (999,000) Securities of Government Sponsored Entities 1,981,000 (16,000) — — 1,981,000 (16,000) Total $ 31,662,000 $ (116,000) $ 74,452,000 $ (972,000) $ 106,114,000 $ (1,088,000)

Organization and Basis of Pre_2

Organization and Basis of Presentation (Policies)	3 Months Ended
	Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	Basis of PresentationThe accompanying financial information has been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”) for interim reporting purposes. The condensed consolidated financial statements are unaudited. The unaudited condensed consolidated financial statements reflect, in the opinion of the Company’s management, all adjustments, consisting of only normal recurring adjustments, necessary for a fair presentation of financial position, results of operations, changes in equity, and comprehensive loss and cash flows for each period presented in accordance with United States generally accepted accounting principles (“U.S. GAAP”). All intercompany transactions and balances have been eliminated. The operating results presented in these unaudited interim condensed financial statements are not necessarily indicative of the results that may be expected for any future periods. These interim unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022.
Reclassifications	Reclassifications Certain amounts reported in prior years have been reclassified to conform with the presentation in the current year. These reclassifications had no effect on the reported results of operations.
Liquidity and Going Concern	Liquidity and Going Concern The Company has experienced recurring net losses from operations, negative cash flows from operating activities, and accumulated deficit since its inception and expects to continue to incur net losses into the foreseeable future. As of March 31, 2023, the Company had approximately $4.1 million in cash and cash equivalents, $91.7 million in short term investments, and working capital of $104.4 million. The Company has an accumulated deficit of $385.8 million as of March 31, 2023. During the three months ended March 31, 2023, the Company used $32.4 million cash in operations. Management expects operating losses and negative cash flows to continue for at least the next year as the Company continues to incur costs related to research and commercialization efforts. Management has prepared cash flows forecasts which indicate that based on the Company’s expected operating losses and negative cash flows, there is substantial doubt about the Company’s ability to continue as a going concern within twelve months after the date that the unaudited condensed consolidated financial statements for the three months ended March 31, 2023, are issued. Management’s ability to continue as a going concern is dependent upon its ability to raise additional funding. Management’s plans to raise additional capital to fulfill its operating and capital requirements for at least 12 months include public or private equity or debt financings. However, the Company may not be able to secure such financing in a timely manner or on favorable terms, if at all. Furthermore, if the Company issues equity securities to raise additional funds, its existing stockholders may experience dilution, and the new equity securities may have rights, preferences and privileges senior to those of the Company’s existing stockholders. The unaudited condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and settlement of liabilities in the normal course of business, and do not include any adjustments to reflect the outcome of this uncertainty.
Recently Adopted Accounting Pronouncements	Recently Adopted Accounting Pronouncements In February 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-13, Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments (ASU 2016-13), which amends the impairment model by requiring entities to use a forward looking approach based on expected losses to estimate credit losses on certain types of financial instruments, including trade receivables and available for sale debt securities. For trade receivables and other instruments, entities will be required to use a new forward-looking expected loss model that generally will result in the earlier recognition of allowances for losses. For available-for-sale debt securities with unrealized losses, the losses will be recognized as allowances rather than as reductions in the amortized cost of the securities. The Company adopted ASU 2016-13 as of January 1, 2023.

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	3 Months Ended
	Mar. 31, 2023
Earnings Per Share [Abstract]
Schedule of Potentially Dilutive Securities not Included in Calculation of Diluted Net Loss Per Share Attributable to Common Stockholders	Potentially dilutive securities not included in the calculation of diluted net loss per share attributable to common stockholders because to do so would be anti-dilutive are as follows (in common stock equivalent shares): March 31, March 31, Stock options 32,013,000 21,531,000 Unvested restricted stock — 4,257,000 Warrants 4,356,000 4,356,000 RSUs 2,457,000 296,000 PSUs 290,000 290,000 Total 39,116,000 30,730,000

Revenue Recognition (Tables)

Revenue Recognition (Tables)	3 Months Ended
	Mar. 31, 2023
Revenue from Contract with Customer [Abstract]
Schedule of Revenue Recognition	Revenue by Source Three Months Ended March 31, 2023 2022 Instruments $ 1,896,000 $ 1,596,000 Consumables 2,235,000 1,520,000 Software 1,316,000 1,090,000 Total product revenue 5,447,000 4,206,000 Service and other 1,968,000 1,490,000 Total revenue $ 7,415,000 $ 5,696,000 The Company has revised the classification of its revenue between the categories in the table above for the March 31, 2022 statement of operations. In the March 31, 2022 statement of operations, “software” was included in “service and other.” Revenue by Geographic Location Three Months Ended March 31, 2023 2022 $ % $ % Americas $ 3,444,000 47 % $ 3,328,000 58 % EMEA 2,992,000 40 % 1,739,000 31 % Asia Pacific 979,000 13 % 629,000 11 % Total $ 7,415,000 100 % $ 5,696,000 100 %

Balance Sheet Account Details (

Balance Sheet Account Details (Tables)	3 Months Ended
	Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Accounts Receivable	March 31, December 31, Accounts receivable, net: Accounts receivable, trade $ 7,030,000 $ 7,315,000 Allowance for credit losses (250,000) (293,000) $ 6,780,000 $ 7,022,000
Schedule of Allowance for Credit Losses	Changes to the allowance for credit losses during the three months ended March 31, 2023 were as follows: Allowance for Credit Losses Balance as of January 1, 2023 $ (293,000) Provision for expected credit loss (5,000) Write-offs and payments 48,000 Balance as of March 31, 2023 $ (250,000)
Schedule of Components of Inventories	The components of inventories are as follows: March 31, December 31, Inventory: Raw materials $ 5,800,000 $ 5,319,000 Work in process 10,003,000 7,055,000 Finished goods 17,310,000 17,387,000 $ 33,113,000 $ 29,761,000
Schedule of Finite-Lived Intangible Assets	Intangible Assets Intangible assets that are subject to amortization consisted of the following for the periods presented: March 31, 2023 December 31, 2022 Gross Carrying Amount Accumulated Amortization Net Carrying Amount Gross Carrying Amount Accumulated Amortization Net Carrying Amount Trade name $ 2,630,000 $ (684,000) $ 1,946,000 $ 2,630,000 $ (552,000) $ 2,078,000 Customer relationships 4,150,000 (1,379,000) 2,771,000 4,150,000 (1,172,000) 2,978,000 Developed technology 41,600,000 (7,068,000) 34,532,000 41,600,000 (5,615,000) 35,985,000 Intangibles, net $ 48,380,000 $ (9,131,000) $ 39,249,000 $ 48,380,000 $ (7,339,000) $ 41,041,000
Schedule of Accrued Liabilities	Accrued expenses consist of the following: March 31, December 31, Compensation expenses $ 6,349,000 $ 7,002,000 Customer deposits 17,000 17,000 Taxes payable 848,000 825,000 Insurance 326,000 613,000 Professional fees and royalties 96,000 210,000 Warranty liabilities 591,000 489,000 Accrued clinical study fees 174,000 250,000 Other 849,000 1,146,000 Total $ 9,250,000 $ 10,552,000

Stockholders_ Equity and Stoc_2

Stockholders’ Equity and Stock-Based Compensation (Tables)	3 Months Ended
	Mar. 31, 2023
Share-Based Payment Arrangement [Abstract]
Schedule of Warrant Activity	A summary of the Company’s warrant activity during the three months ended March 31, 2023 was as follows: Shares of Stock under Warrants Weighted- Weighted- Aggregate Outstanding at January 1, 2023 4,356,000 $ 5.96 0.76 $ 273,000 Granted — — — — Exercised — — — — Canceled — — — — Outstanding at March 31, 2023 4,356,000 $ 5.96 0.52 $ 156,000
Schedule of Stock Option Activity	A summary of the Company’s stock option activity during the three months ended March 31, 2023 was as follows: Shares of Stock under Stock Options Weighted- Weighted- Aggregate Outstanding at January 1, 2023 24,022,000 $ 3.28 8.50 $ 2,068,000 Granted 9,121,000 1.60 — Exercised (42,000) 0.55 — 25,000 Canceled (1,088,000) 3.37 — Outstanding at March 31, 2023 32,013,000 $ 2.80 8.84 $ 1,147,000 Vested and exercisable at March 31, 2023 9,149,000 $ 3.56 7.89 $ 892,000
Schedule of Recognized Stock-Based Compensation Expense	The Company recognized stock-based compensation expense for the periods presented as follows: Three Months Ended 2023 2022 Cost of product revenue $ 102,000 $ — Cost of service and other revenue 44,000 — Research and development 1,357,000 3,328,000 General and administrative 2,379,000 1,774,000 Total stock-based compensation expense $ 3,882,000 $ 5,102,000
Schedule of Weighted-Average Assumptions in Black -Scholes Option Pricing Model	The weighted-average assumptions used in the Black-Scholes option pricing model to determine the fair value of the employee stock option grants during the periods presented were as follows: Three Months Ended 2023 2022 Risk-free interest rate 4.0 % 1.9 % Expected volatility 72.7 % 70.1 % Expected term (in years) 6.0 6.0 Expected dividend yield 0.0 % 0.0 %
Schedule of Restricted Stock Units and Performance Stock Units	The following table summarizes RSU activity during the three months ended March 31, 2023: Stock Units Weighted- Average Grant Date Fair Value per Share Outstanding at January 1, 2023 96,000 $ 4.74 Granted 2,461,000 1.63 Released (65,000) 4.74 Forfeited (35,000) 1.63 Outstanding at March 31, 2023 2,457,000 $ 1.67 The following table summarizes PSU activity during the three months ended March 31, 2023: Stock Units Weighted- Average Grant Date Fair Value per Share Outstanding at January 1, 2023 290,000 $ 4.74 Granted — — Released — — Forfeited — — Outstanding at March 31, 2023 290,000 $ 4.74

Commitment and Contingencies (T

Commitment and Contingencies (Tables)	3 Months Ended
	Mar. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
Schedule of Lessee, Operating Lease, Liability, Maturity	The future minimum payments under non-cancellable operating and finance leases as of March 31, 2023, are as follows: Operating Leases Finance Lease Remainder of 2023 $ 1,942,000 $ 242,000 2024 2,684,000 330,000 2025 2,788,000 338,000 2026 729,000 347,000 2027 255,000 356,000 Thereafter — 5,594,000 Total future lease payments 8,398,000 7,207,000 Less: imputed interest (1,120,000) (3,313,000) Total lease liabilities $ 7,278,000 $ 3,894,000

Acquisitions (Tables)

Acquisitions (Tables)	3 Months Ended
	Mar. 31, 2023
Business Combination and Asset Acquisition [Abstract]
Schedule of Business Acquisitions	The following is the estimated purchase price for the acquisition of Purigen: Cash $ 32,034,000 Estimated fair value of milestone consideration 12,970,000 Estimated return of cash to buyer from escrow (90,000) Total estimated purchase price $ 44,914,000
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed	The total estimated purchase price was allocated to Purigen’s tangible and identifiable intangible assets acquired and liabilities assumed based on their estimated fair values as of the acquisition date, with the excess recorded as goodwill, as follows: Cash & cash equivalents $ 290,000 Accounts receivable 259,000 Inventory 944,000 Prepaid expenses and other current assets 184,000 Property and equipment, net 805,000 Restricted cash 400,000 Operating lease right-of-use assets 1,636,000 Other long-term assets 533,000 Intangible assets 20,000,000 Goodwill 22,651,000 Accounts payable and other accrued liabilities (1,152,000) Operating lease liability (short-term and long-term) (1,636,000) Net assets acquired $ 44,914,000
Schedule of Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination	The acquisition date fair values of identifiable intangible assets acquired are as following: Developed technology $ 18,800,000 Customer relationships 200,000 Tradename 1,000,000 Fair value of identifiable intangible assets $ 20,000,000
Schedule of Business Acquisition, Pro Forma Information	The following unaudited pro forma financial information is for informational purposes only and is not necessarily indicative of the results of operations that would have been achieved as if the acquisition had taken place as of January 1, 2021. Three Months Ended March 31, 2022 Revenue $ 6,220,000 Net loss (32,048,000) Basic and diluted net loss per share $ (0.11)

Investments and Fair Value Me_2

Investments and Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2023
Fair Value Disclosures [Abstract]
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis	The following table presents the Company’s financial assets and liabilities measured at fair value on a recurring basis as of March 31, 2023 and December 31, 2022: March 31, 2023 Total Fair Value and Carrying Value on Balance Sheet Fair Value Measurement Category Level 1 Level 2 Level 3 Assets: Commercial paper $ 15,216,000 $ — $ 15,216,000 $ — Corporate notes/bonds 74,500,000 — 74,500,000 — Securities of government sponsored entities 1,988,000 — 1,988,000 — Total investments: $ 91,704,000 $ — $ 91,704,000 $ — Money market funds $ 252,000 $ 252,000 $ — $ — Liabilities: Contingent consideration $ 23,141,000 $ — $ — $ 23,141,000 December 31, 2022 Total Fair Value and Carrying Value on Balance Sheet Fair Value Measurement Category Level 1 Level 2 Level 3 Assets: Commercial paper $ 20,020,000 $ — $ 20,020,000 $ — Corporate notes/bonds 86,094,000 — 86,094,000 — Securities of government sponsored entities 1,981,000 1,981,000 Total investments: $ 108,095,000 $ — $ 108,095,000 $ — Money market funds $ 1,868,000 $ 1,868,000 $ — $ — Liabilities: Contingent consideration $ 22,352,000 $ — $ — $ 22,352,000
Schedule of Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation	Changes in estimated fair value of contingent consideration liability in the three months ended March 31, 2023 is as follows: Contingent Consideration Liability (Level 3 Measurement) Balance as of January 1, 2023 $ 22,352,000 Liability recorded as a result of current period acquisition — Change in estimated fair value, recorded in selling, general and administrative expenses 789,000 Cash payments — Balance as of March 31, 2023 $ 23,141,000
Schedule of Marketable Securities	As of March 31, 2023, the following table summarizes the amortized cost and the unrealized gains/losses of the available for sale securities: Remaining Contractual Maturity (in years) Amortized Cost Unrealized Gains Unrealized Losses Aggregate Estimated Fair Value Commercial paper Less than 1 $ 15,259,000 $ — $ (43,000) $ 15,216,000 Corporate notes/bonds Less than 1 68,739,000 — (561,000) 68,178,000 Securities of government sponsored entities Less than 1 1,998,000 — (10,000) 1,988,000 Total maturity less than 1 year $ 85,996,000 $ — $ (614,000) $ 85,382,000 Corporate notes/bonds 1 to 5 6,372,000 — (50,000) 6,322,000 Total $ 92,368,000 $ — $ (664,000) $ 91,704,000 As of December 31, 2022, the following table summarizes the amortized cost and the unrealized gains/losses of the available for sale securities: Remaining Contractual Maturity (in years) Amortized Cost Unrealized Gains Unrealized Losses Aggregate Estimated Fair Value Commercial paper Less than 1 $ 20,093,000 $ — $ (73,000) $ 20,020,000 Corporate notes/bonds Less than 1 72,823,000 1,000 (911,000) 71,913,000 Securities of government sponsored entities Less than 1 1,998,000 — (16,000) 1,982,000 Total maturity less than 1 year $ 94,914,000 $ 1,000 $ (1,000,000) $ 93,915,000 Corporate notes/bonds 1 to 5 14,268,000 — (88,000) 14,180,000 Total $ 109,182,000 $ 1,000 $ (1,088,000) $ 108,095,000 As of March 31, 2023, the following table summarizes available-for-sale securities in an unrealized loss position with no credit losses reported: Less Than 12 Months 12 Months or Greater Total Fair Value Gross Unrealized Loss Fair Value Gross Unrealized Loss Fair Value Gross Unrealized Loss Commercial paper $ 15,216,000 $ (43,000) $ — $ — $ 15,216,000 $ (43,000) Corporate Notes/Bonds 11,687,000 (40,000) 62,813,000 (571,000) 74,500,000 (611,000) Securities of Government Sponsored Entities 1,988,000 (10,000) — — 1,988,000 (10,000) Total $ 28,891,000 $ (93,000) $ 62,813,000 $ (571,000) $ 91,704,000 $ (664,000) As of December 31, 2022, the following table summarizes available-for-sale securities in an unrealized loss position with no credit losses reported: Less Than 12 Months 12 Months or Greater Total Fair Value Gross Unrealized Loss Fair Value Gross Unrealized Loss Fair Value Gross Unrealized Loss Commercial paper $ 20,020,000 $ (73,000) $ — $ — $ 20,020,000 $ (73,000) Corporate Notes/Bonds 9,661,000 (27,000) 74,452,000 (972,000) 84,113,000 (999,000) Securities of Government Sponsored Entities 1,981,000 (16,000) — — 1,981,000 (16,000) Total $ 31,662,000 $ (116,000) $ 74,452,000 $ (972,000) $ 106,114,000 $ (1,088,000)

Organization and Basis of Pre_3

Organization and Basis of Presentation (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Cash and cash equivalents	$ 4,104	$ 24,048	$ 5,091
Investments	91,704		108,095
Working capital	104,400
Accumulated deficit	385,839		$ 348,715
Net cash used in operating activities	$ 32,413	$ 32,494

Net Loss Per Share (Details)

Net Loss Per Share (Details) - shares shares in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share amount (in shares)	39,116	30,730
Stock options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share amount (in shares)	32,013	21,531
Unvested restricted stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share amount (in shares)	0	4,257
Warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share amount (in shares)	4,356	4,356
RSUs
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share amount (in shares)	2,457	296
PSUs
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share amount (in shares)	290	290

Revenue Recognition - Revenue b

Revenue Recognition - Revenue by Source and Geographic Location (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Disaggregation of Revenue [Line Items]
Revenue	$ 7,415	$ 5,696
Americas
Disaggregation of Revenue [Line Items]
Revenue	3,444	3,328
EMEA
Disaggregation of Revenue [Line Items]
Revenue	2,992	1,739
Asia Pacific
Disaggregation of Revenue [Line Items]
Revenue	$ 979	$ 629
Revenue from Contract with Customer | Geographic Concentration Risk
Disaggregation of Revenue [Line Items]
Concentration risk percentage	100%	100%
Revenue from Contract with Customer | Geographic Concentration Risk | Americas
Disaggregation of Revenue [Line Items]
Concentration risk percentage	47%	58%
Revenue from Contract with Customer | Geographic Concentration Risk | EMEA
Disaggregation of Revenue [Line Items]
Concentration risk percentage	40%	31%
Revenue from Contract with Customer | Geographic Concentration Risk | Asia Pacific
Disaggregation of Revenue [Line Items]
Concentration risk percentage	13%	11%
Product revenue
Disaggregation of Revenue [Line Items]
Revenue	$ 5,447	$ 4,206
Instruments
Disaggregation of Revenue [Line Items]
Revenue	1,896	1,596
Consumables
Disaggregation of Revenue [Line Items]
Revenue	2,235	1,520
Software
Disaggregation of Revenue [Line Items]
Revenue	1,316	1,090
Service and other
Disaggregation of Revenue [Line Items]
Revenue	$ 1,968	$ 1,490

Revenue Recognition - Narrative

Revenue Recognition - Narrative (Details)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Geographic Concentration Risk | Revenue Benchmark | United States
Disaggregation of Revenue [Line Items]
Concentration risk percentage	41.20%	45%

Revenue Recognition - Remaining

Revenue Recognition - Remaining Performance Obligations (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Performance obligation	$ 1.3
Revenue recognized	$ 0.7	$ 0.3
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-04-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Performance obligation, percentage	74.90%
Timing of satisfaction of remaining performance obligation	9 months
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Performance obligation, percentage	20.50%
Timing of satisfaction of remaining performance obligation	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Performance obligation, percentage	4.60%
Timing of satisfaction of remaining performance obligation	1 year

Balance Sheet Account Details -

Balance Sheet Account Details - Schedule of Accounts Receivable (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accounts receivable, trade	$ 7,030	$ 7,315
Allowance for credit losses	(250)	(293)
Accounts receivable, net	$ 6,780	$ 7,022

Balance Sheet Account Details_2

Balance Sheet Account Details - Schedule of Allowance for Credit Losses (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2023 USD ($)
Accounts Receivable, Allowance for Credit Loss [Roll Forward]
Beginning balance	$ (293)
Provision for expected credit loss	(5)
Write-offs and payments	48
Ending balance	$ (250)

Balance Sheet Account Details_3

Balance Sheet Account Details - Schedule of Components of Inventories (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Raw materials	$ 5,800	$ 5,319
Work in process	10,003	7,055
Finished goods	17,310	17,387
Inventory, net	$ 33,113	$ 29,761

Balance Sheet Account Details_4

Balance Sheet Account Details - Schedule of Intangible Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 48,380	$ 48,380
Accumulated Amortization	(9,131)	(7,339)
Net Carrying Amount	39,249	41,041
Tradename
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	2,630	2,630
Accumulated Amortization	(684)	(552)
Net Carrying Amount	1,946	2,078
Customer relationships
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	4,150	4,150
Accumulated Amortization	(1,379)	(1,172)
Net Carrying Amount	2,771	2,978
Developed technology
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	41,600	41,600
Accumulated Amortization	(7,068)	(5,615)
Net Carrying Amount	$ 34,532	$ 35,985

Balance Sheet Account Details_5

Balance Sheet Account Details - Narrative (Details) - USD ($) $ in Millions	Mar. 31, 2023	Dec. 31, 2022
Internet Domain Names
Finite-Lived Intangible Assets [Line Items]
Intangible assets not subject to amortization	$ 0.1	$ 0.1

Balance Sheet Account Details_6

Balance Sheet Account Details - Schedule of Accrued Expenses (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Compensation expenses	$ 6,349	$ 7,002
Customer deposits	17	17
Taxes payable	848	825
Insurance	326	613
Professional fees and royalties	96	210
Warranty liabilities	591	489
Accrued clinical study fees	174	250
Other	849	1,146
Accrued expenses	$ 9,250	$ 10,552

Stockholders_ Equity and Stoc_3

Stockholders’ Equity and Stock-Based Compensation - Narrative (Details) $ / shares in Units, $ in Millions						1 Months Ended		3 Months Ended
	Apr. 13, 2023 vote $ / shares shares	Mar. 09, 2023 USD ($)	Feb. 15, 2023 installment $ / shares shares	Oct. 04, 2022 USD ($) $ / shares	Mar. 23, 2021 USD ($)	Aug. 31, 2022 USD ($) $ / shares shares	Oct. 31, 2021 $ / shares shares	Mar. 31, 2023 USD ($) $ / shares shares	Dec. 31, 2022 $ / shares
Class of Stock [Line Items]
Number of shares issued (in shares) | shares						6,600,000		9,500,000
Average share price (in dollars per share)						$ 3.46		$ 1.60
Net proceeds | $						$ 23.1		$ 15.2
Offering costs | $						$ 0.6		$ 0.4
Weighted-average grant date fair value (in dollars per share)								$ 1.07
Granted (in shares) | shares								9,121,000
Granted (in dollars per share)								$ 1.60
Subsequent Event
Class of Stock [Line Items]
Reverse stock split, percentage of outstanding common stock are present	33%
Series A Preferred Stock
Class of Stock [Line Items]
Preferred stock, par value (in dollars per share)								$ 0.0001	$ 0.0001
Series A Preferred Stock | Subsequent Event
Class of Stock [Line Items]
Preferred stock, number of votes | vote	3,000,000,000
Preferred stock, redemption price (in dollars per share)	$ 100
Executive Officer
Class of Stock [Line Items]
Granted (in shares) | shares			3,300,000
Granted (in dollars per share)			$ 1.63
David Barker | Series A Preferred Stock | Subsequent Event
Class of Stock [Line Items]
Average share price (in dollars per share)	$ 100
Stock issued during period (in shares) | shares	1
Preferred stock, par value (in dollars per share)	$ 0.0001
Restricted Stock
Class of Stock [Line Items]
Grant fair value (in dollars per share)				$ 2.04
Reduction in stock-based compensation cost from modification | $				$ 15.8
Vesting period								4 years
Restricted Stock | Vesting on October 18, 2022
Class of Stock [Line Items]
Granted vesting percentage							33%
Restricted Stock | Vesting every three months following October 18, 2022
Class of Stock [Line Items]
Granted vesting percentage							8%
Restricted Stock | BioDiscovery
Class of Stock [Line Items]
Units granted (in shares) | shares							5,000,000
Granted (in dollars per share)							$ 5.20
RSUs
Class of Stock [Line Items]
Units granted (in shares) | shares								2,461,000
Granted (in dollars per share)								$ 1.63
Grant fair value (in dollars per share)								$ 1.67	4.74
Total intrinsic value | $								$ 0.3
Weighted average remaining contractual term								3 years 6 months
RSUs | Executive Officer
Class of Stock [Line Items]
Granted (in shares) | shares			700,000
Number of successive annual installments | installment			3
PSUs
Class of Stock [Line Items]
Units granted (in shares) | shares								0
Granted (in dollars per share)								$ 0
Grant fair value (in dollars per share)								$ 4.74	$ 4.74
Weighted average remaining contractual term								2 years 1 month 6 days
Option | Executive Officer
Class of Stock [Line Items]
Vesting period			48 months
Cowen
Class of Stock [Line Items]
Aggregate offering price | $		$ 200			$ 350
Commission fee					3%

Stockholders_ Equity and Stoc_4

Stockholders’ Equity and Stock-Based Compensation - Warrant Activity (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Shares of Stock under Warrants
Beginning balance (in shares)	4,356
Granted (in shares)	0
Exercised (in shares)	0
Canceled (in shares)	0
Ending balance (in shares)	4,356	4,356
Weighted- Average Exercise Price
Beginning balance (in dollars per share)	$ 5.96
Ending balance (in dollars per share)	$ 5.96	$ 5.96
Weighted- Average Remaining Contractual Term
Balance	6 months 7 days	9 months 3 days
Aggregate Intrinsic Value
Beginning balance	$ 273
Ending balance	$ 156	$ 273

Stockholders_ Equity and Stoc_5

Stockholders’ Equity and Stock-Based Compensation - Schedule of Stock Option Activity (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Shares of Stock under Stock Options
Beginning balance (in shares)	24,022
Granted (in shares)	9,121
Exercised (in shares)	(42)
Canceled (in shares)	(1,088)
Ending balance (in shares)	32,013	24,022
Vested and exercisable (in shares)	9,149
Weighted- Average Exercise Price
Beginning balance (in dollars per share)	$ 3.28
Granted (in dollars per share)	1.60
Exercised (in dollars per share)	0.55
Canceled (in dollars per share)	3.37
Ending balance (in dollars per share)	2.80	$ 3.28
Vested and exercisable (in dollars per share)	$ 3.56
Weighted- Average Remaining Contractual Term
Outstanding (in years)	8 years 10 months 2 days	8 years 6 months
Vested and exercisable (in years)	7 years 10 months 20 days
Aggregate Intrinsic Value
Beginning balance	$ 2,068
Exercised	25
Ending balance	1,147	$ 2,068
Vested and exercisable	$ 892

Stockholders_ Equity and Stoc_6

Stockholders’ Equity and Stock-Based Compensation - Recognized Stock-Based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	$ 3,882	$ 5,102
Cost of product revenue
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	102	0
Cost of service and other revenue
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	44	0
Research and development
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	1,357	3,328
General and administrative
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	$ 2,379	$ 1,774

Stockholders_ Equity and Stoc_7

Stockholders’ Equity and Stock-Based Compensation - Assumptions (Details)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Share-Based Payment Arrangement [Abstract]
Risk-free interest rate	4%	1.90%
Expected volatility	72.70%	70.10%
Expected term (in years)	6 years	6 years
Expected dividend yield	0%	0%

Stockholders_ Equity and Stoc_8

Stockholders’ Equity and Stock-Based Compensation - Restricted Stock and Performance Stock Activity (Details) shares in Thousands	3 Months Ended
	Mar. 31, 2023 $ / shares shares
RSUs
Stock Units
Beginning balance (in shares) | shares	96
Units granted (in shares) | shares	2,461
Released (in shares) | shares	(65)
Forfeited (in shares) | shares	(35)
Ending balance (in shares) | shares	2,457
Weighted- Average Grant Date Fair Value per Share
Beginning balance (in dollars per share) | $ / shares	$ 4.74
Granted (in dollars per share) | $ / shares	1.63
Released (in dollars per share) | $ / shares	4.74
Forfeited (in dollars per share) | $ / shares	1.63
Ending balance (in dollars per share) | $ / shares	$ 1.67
PSUs
Stock Units
Beginning balance (in shares) | shares	290
Units granted (in shares) | shares	0
Released (in shares) | shares	0
Forfeited (in shares) | shares	0
Ending balance (in shares) | shares	290
Weighted- Average Grant Date Fair Value per Share
Beginning balance (in dollars per share) | $ / shares	$ 4.74
Granted (in dollars per share) | $ / shares	0
Released (in dollars per share) | $ / shares	0
Forfeited (in dollars per share) | $ / shares	0
Ending balance (in dollars per share) | $ / shares	$ 4.74

Commitments and Contingencies -

Commitments and Contingencies - Summary of Undiscounted Future Non-Cancellable Lease Payments Under Leases (Details) $ in Thousands	Mar. 31, 2023 USD ($)
Operating Leases
Remainder of 2023	$ 1,942
2024	2,684
2025	2,788
2026	729
2027	255
Thereafter	0
Total future lease payments	8,398
Less: imputed interest	(1,120)
Total lease liabilities	7,278
Finance Lease
Remainder of 2023	242
2024	330
2025	338
2026	347
2027	356
Thereafter	5,594
Total future lease payments	7,207
Less: imputed interest	(3,313)
Total lease liabilities	$ 3,894

Acquisitions - Narrative (Detai

Acquisitions - Narrative (Details) - Purigen $ in Thousands	1 Months Ended
	Nov. 30, 2022 USD ($)
Business Acquisition [Line Items]
Cash consideration transferred in acquisition	$ 32,034
Consideration milestone payment, maximum	32,000
Cash held in escrow fund	$ 1,200
Customer relationships
Business Acquisition [Line Items]
Intangible assets useful life	5 years
Tradename
Business Acquisition [Line Items]
Intangible assets useful life	5 years
Developed technology
Business Acquisition [Line Items]
Intangible assets useful life	15 years

Acquisitions - Acquisition Purc

Acquisitions - Acquisition Purchase Price (Details) - Purigen $ in Thousands	1 Months Ended
	Nov. 30, 2022 USD ($)
Business Acquisition [Line Items]
Payments to Acquire Businesses, Gross	$ 32,034
Estimated fair value of milestone consideration	12,970
Estimated return of cash to buyer from escrow	(90)
Total estimated purchase price	$ 44,914

Acquisitions - Fair Value of Ta

Acquisitions - Fair Value of Tangible and Identifiable Assets Acquired and Liabilities Assumed (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022	Nov. 30, 2022
Business Acquisition [Line Items]
Goodwill	$ 77,289	$ 77,289
Purigen
Business Acquisition [Line Items]
Cash & cash equivalents			$ 290
Accounts receivable			259
Inventory			944
Prepaid expenses and other current assets			184
Property and equipment, net			805
Restricted cash			400
Operating lease right-of-use assets			1,636
Other long-term assets			533
Intangible assets			20,000
Goodwill			22,651
Accounts payable and other accrued liabilities			(1,152)
Operating lease liability (short-term and long-term)			(1,636)
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net, Total			$ 44,914

Acquisitions - Identifiable Int

Acquisitions - Identifiable Intangible Assets (Details) - Purigen $ in Thousands	Nov. 30, 2022 USD ($)
Business Acquisition [Line Items]
Intangible assets	$ 20,000
Developed technology
Business Acquisition [Line Items]
Intangible assets	18,800
Customer relationships
Business Acquisition [Line Items]
Intangible assets	200
Tradename
Business Acquisition [Line Items]
Intangible assets	$ 1,000

Acquisitions - Pro Forma Inform

Acquisitions - Pro Forma Information (Details) - Purigen $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2022 USD ($) $ / shares
Business Acquisition [Line Items]
Revenue | $	$ 6,220
Net loss | $	$ (32,048)
Basic net loss per share (in dollars per share) | $ / shares	$ (0.11)
Diluted net loss per share (in dollars per share) | $ / shares	$ (0.11)

Investments and Fair Value Me_3

Investments and Fair Value Measurements - Financial Assets and Liabilities (Details) - Fair Value, Recurring - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Contingent consideration
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Liabilities	$ 23,141	$ 22,352
Total investments
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets	91,704	108,095
Total investments | Commercial paper
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets	15,216	20,020
Total investments | Corporate notes/bonds
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets	74,500	86,094
Total investments | Securities of government sponsored entities
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets	1,988	1,981
Money market funds
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets	252	1,868
Level 1 | Contingent consideration
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Liabilities	0	0
Level 1 | Total investments
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets	0	0
Level 1 | Total investments | Commercial paper
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets	0	0
Level 1 | Total investments | Corporate notes/bonds
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets	0	0
Level 1 | Total investments | Securities of government sponsored entities
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets	0
Level 1 | Money market funds
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets	252	1,868
Level 2 | Contingent consideration
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Liabilities	0	0
Level 2 | Total investments
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets	91,704	108,095
Level 2 | Total investments | Commercial paper
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets	15,216	20,020
Level 2 | Total investments | Corporate notes/bonds
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets	74,500	86,094
Level 2 | Total investments | Securities of government sponsored entities
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets	1,988	1,981
Level 2 | Money market funds
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets	0	0
Level 3 | Contingent consideration
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Liabilities	23,141	22,352
Level 3 | Total investments
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets	0	0
Level 3 | Total investments | Commercial paper
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets	0	0
Level 3 | Total investments | Corporate notes/bonds
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets	0	0
Level 3 | Total investments | Securities of government sponsored entities
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets	0
Level 3 | Money market funds
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets	$ 0	$ 0

Investments and Fair Value Me_4

Investments and Fair Value Measurements - Narrative (Details) $ in Millions	3 Months Ended
	Mar. 31, 2023 USD ($) security	Dec. 31, 2022 USD ($) security
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Number of securities in an unrealized loss position, less than 12 months | security	17	16
Number of securities in an unrealized loss position, greater than 12 months | security	19	24
Interest receivable	$ 0.6	$ 0.5
Contingent consideration | Purigen
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Consideration milestone payment, maximum	$ 32
Contingent consideration | Measurement Input, Discount Rate
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Measurement input	0.03
Contingent consideration | Measurement Input, Discount Rate | Purigen
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Measurement input	0.15
Contingent consideration | Measurement Input, Probability Factor | BioDiscovery
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Measurement input	0.95
Consideration milestone payment	$ 10
Contingent consideration | Measurement Input, Probability Factor | Purigen | Minimum
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Measurement input	0.20
Contingent consideration | Measurement Input, Probability Factor | Purigen | Maximum
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Measurement input	0.80

Investments and Fair Value Me_5

Investments and Fair Value Measurements - Contingent Consideration Liability (Details) - Contingent consideration $ in Thousands	3 Months Ended
	Mar. 31, 2023 USD ($)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	$ 22,352
Liability recorded as a result of current period acquisition	0
Change in estimated fair value, recorded in selling, general and administrative expenses	789
Cash payments	0
Ending balance	$ 23,141

Investments and Fair Value Me_6

Investments and Fair Value Measurements - Amortized Cost and Unrealized Gains (Losses) (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Amortized Cost
Less than 1 year	$ 85,996	$ 94,914
Total	92,368	109,182
Unrealized Gains
Less than 1 year	0	1
Total	0	1
Unrealized Losses
Less than 1 year	(614)	(1,000)
Total	(664)	(1,088)
Aggregate Estimated Fair Value
Less than 1 year	85,382	93,915
Total	91,704	108,095
Commercial paper
Amortized Cost
Less than 1 year	15,259	20,093
Unrealized Gains
Less than 1 year	0	0
Unrealized Losses
Less than 1 year	(43)	(73)
Aggregate Estimated Fair Value
Less than 1 year	15,216	20,020
Corporate notes/bonds
Amortized Cost
Less than 1 year	68,739	72,823
Due after one year through five years	6,372	14,268
Unrealized Gains
Less than 1 year	0	1
Due after one year through five years	0	0
Unrealized Losses
Less than 1 year	(561)	(911)
Due after one year through five years	(50)	(88)
Aggregate Estimated Fair Value
Less than 1 year	68,178	71,913
Due after one year through five years	6,322	14,180
Securities of government sponsored entities
Amortized Cost
Less than 1 year	1,998	1,998
Unrealized Gains
Less than 1 year	0	0
Unrealized Losses
Less than 1 year	(10)	(16)
Aggregate Estimated Fair Value
Less than 1 year	$ 1,988	$ 1,982

Investments and Fair Value Me_7

Investments and Fair Value Measurements - Unrealized Losses Positions (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Fair Value
Less Than 12 Months, Fair Value	$ 28,891	$ 31,662
12 Months or Greater, Fair Value	62,813	74,452
Total	91,704	106,114
Gross Unrealized Loss
Less than 12 months, Gross Unrealized Loss	(93)	(116)
12 Months or Greater, Gross Unrealized Loss	(571)	(972)
Securities of government sponsored entities	(664)	(1,088)
Commercial paper
Fair Value
Less Than 12 Months, Fair Value	15,216	20,020
12 Months or Greater, Fair Value	0	0
Total	15,216	20,020
Gross Unrealized Loss
Less than 12 months, Gross Unrealized Loss	(43)	(73)
12 Months or Greater, Gross Unrealized Loss	0	0
Securities of government sponsored entities	(43)	(73)
Corporate notes/bonds
Fair Value
Less Than 12 Months, Fair Value	11,687	9,661
12 Months or Greater, Fair Value	62,813	74,452
Total	74,500	84,113
Gross Unrealized Loss
Less than 12 months, Gross Unrealized Loss	(40)	(27)
12 Months or Greater, Gross Unrealized Loss	(571)	(972)
Securities of government sponsored entities	(611)	(999)
Securities of government sponsored entities
Fair Value
Less Than 12 Months, Fair Value	1,988	1,981
12 Months or Greater, Fair Value	0	0
Total	1,988	1,981
Gross Unrealized Loss
Less than 12 months, Gross Unrealized Loss	(10)	(16)
12 Months or Greater, Gross Unrealized Loss	0	0
Securities of government sponsored entities	$ (10)	$ (16)